FoldIt Game Uses Competition To Solve Protein Structures

While computer gamers have long used gaming to interact with one another, build social connections, and de-stress, it’s now possible to contribute to scientific exploration while gaming. A new computer game called FoldIt encourages gamers to attempt to fold proteins into the lowest energy structure.

FoldIt screen

From the FoldIt website:

[K]nowing the structure of a protein is key to understanding how it works and to targeting it with drugs. A small protein can consist of 100 amino acids, while some human proteins can be huge (1000 amino acids). The number of different ways even a small protein can fold is astronomical because there are so many degrees of freedom. Figuring out which of the many, many possible structures is the best one is regarded as one of the hardest problems in biology today and current methods take a lot of money and time, even for computers. Foldit attempts to predict the structure of a protein by taking advantage of humans’ puzzle-solving intuitions and having people play competitively to fold the best proteins.

Already, gamers playing FoldIt have made scientific breakthroughs; it took gamers only ten days to solve the structure of a protein — specifically, a protein that helps the HIV virus to replicate itself — that researchers had been attempting to deduce for a decade.

The strength of the FoldIt game as a mechanism for solving protein structure is that it capitalizes on the spatial reasoning skills of humans, which even highly advanced computers lack. Proteins are large, three-dimensional molecules, and while computers move through a long sequence of trials in an attempt to find the lowest energy structure, humans can use intuition developed through a shorter trial-and-error sequence. The competitive nature of the online game allows gamers to learn from the mistakes of others and combines intellectual resources.

Source: FoldIt

EZ Vein Receives Quick FDA Approval

EZ Vein is designed to ease the sometimes tricky job of inserting an intravenous catheter. The noninvasive device includes an inflation cuff that goes over the arm to redirect blood from deep tissue to the target vein near the skin’s surface to make more visible and accessible to a needle.

EZ Vein

The medical device was invented by Dr. Robert Perry, a resident at Oklahoma University Medical Center. EZ Vein is so practical that federal regulators approved it in just 17 days.

According to Perry:

It was kind of a surprise. I wasn’t anticipating getting anything back until January, and I got it in October.

Source: NewsOK

(HT: Medgadget)

Neoprobe Imaging Agent Aids in Diagnosis of Alzheimer’s Disease

Neoprobe’s newly licensed radiopharmaceutical imaging agent, AZD4694, is a fluorine-18 labeled radioligand for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer’s disease.

Imaging agent for amyloid detection to aid diagnosis of Alzheimers disease

According to Thomas Tulip, Ph.D., Neoprobe’s Executive Vice President and Chief Business Officer:

We believe AZD4694 has a compelling global commercial outlook and should beneficially facilitate development of more effective disease-modifying therapies for Alzheimer’s disease. This potentially powerful second-generation agent with apparent best-in-class properties has demonstrated strong performance attributes. We believe AZD4694 imaging may be quite useful as an adjunct measure in the diagnosis of this large, growing disease and may allow patients to seek earlier, and therefore potentially more effective, treatment options.

An estimated 35 million people worldwide are living with Alzheimer’s and other forms of dementia. A 2009 report by the London-based nonprofit Alzheimer’s Disease International (ADI), an international federation of 71 national Alzheimer organizations (including the Alzheimer’s Association), indicates that the number of people with dementia is expected to grow sharply to 65.7 million in 2030 and 115.4 million in 2050.

AZD4694 binds to beta-amyloid deposits in the brain and can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of Alzheimer’s disease diagnosis and the presence of amyloid pathology is a supportive feature for diagnosis of probable Alzheimer’s disease. Patients who are negative for amyloid pathology do not have Alzheimer’s disease.

Neoprobe Corporation, a Dublin, Ohio-based company, develops and commercializes innovative biomedical products that meet critical intraopertive, diagnostic and therapeutic treatment needs of patients and physicans. In January, Neoprobe will officially change its name to Navidea Biopharmaceuticals to reflect the company’s transformation to a biopharmaceutical company focused on targeted diagnostic agents.

Source: Neoprobe

NLMplus, Semantics for Better Results in Search and Discovery

WebLib, a small international technology startup of experts in information retrieval, natural language processing and medical informatics, recently released NLMplus, a semantic search and knowledge discovery application that utilizes a variety of semantic resources and natural language processing tools to produce improved search results from the vast collection of biomedical data and services of the National Library of Medicine (NLM).

NLMplus

Celebrating Five Years of Highlight HEALTH, Prize Pack Giveaways

Some events are once-in-a-lifetime and just have to be observed. Here at Highlight HEALTH, we’re coming up on one of those events: our five year anniversary!

To celebrate this milestone and to give something back to our readers, for the next three months we’re holding a prize pack giveaway.

5 year anniversary